Your search returned 5 results.

Sort
Results
1.
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. MedStar authors:
  • Swain, Sandra M
PMID:
  • 26272770
Year: 2015
Citation:
  • Lancet Oncology. 16(9):1037-48, 2015 Sep.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Adams PT, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Liu Q, Mamounas EP, Margolese RG, Mehta RS, Paik S, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
2.
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. MedStar authors:
  • Kumar, Anjali S
PMID:
  • 26187751
Citation:
  • Lancet Oncology. 16(8):957-66, 2015 Aug.
Institution:
  • MedStar Washington Hospital Center
Department:
  • Surgery/Colorectal Surgery
Medline publication type:
  • Clinical Trial, Phase II
  • Journal Article
  • Multicenter Study
  • Research Support, N.I.H., Extramural
Form of publication:
  • Journal Article
All authors:
  • Avila K, Cataldo PA, Chow OS, Coutsoftides T, Dietz DW, Fichera A, Garcia-Aguilar J, Herzig DO, Hunt SR, Kumar AS, Marcet JE, Oommen S, Patil S, Polite BN, Smith DD, Stamos MJ, Ternent CA, Timing of Rectal Cancer Response to Chemoradiation Consortium, Varma MG
3.
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. [] MedStar authors:
  • Swain, Sandra M
PMID:
  • 25542269
Year: 2015
Citation:
  • Breast Cancer Research & Treatment. 149(1):163-9, 2015 Jan.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase II
  • Journal Article
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Bhatt K, Bury MJ, Fehrenbacher L, Flynn PJ, Geyer CE Jr, Goel R, Jacobs SA, Johannes H, Julian TB, Mamounas EP, Provencher L, Rastogi P, Robidoux A, Stella PJ, Swain SM, Tan AR, Thirlwell MP, Wolmark N
4.
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
  • Swain, Sandra M
PMID:
  • 27693116
Year: 2017
Citation:
  • Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
5.
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy. [Review] MedStar authors:
  • Desale, Sameer
  • Kodavanti, Preeti Prasad
  • Sampah, Maame Efua
  • Sugarbaker, Paul H
  • Yoon, JaeHee J
PMID:
  • 33500181
Year: 2021
Citation:
  • European Journal of Surgical Oncology. 47(6):1278-1285, 2021 Jun.
Institution:
  • MedStar Health Research Institute
  • Washington Cancer Institute
Medline publication type:
  • Journal Article
  • Review
Form of publication:
  • Journal Article
All authors:
  • Barrak D, Desale S, Dugan MM, Kodavanti PP, Sampah ME, Sugarbaker PH, Yoon JJ
Pages

Powered by Koha